Abstract::
Although immunotherapy and targeted therapy have radically changed melanoma treatment,
the development of resistance and reduction of patient responses are still significant
problems. Small molecule inhibitors are needed to overcome this situation, and biomarkers that
can estimate whether patients will reply to existing treatments need to be developed. miRNAs are
involved in diverse processes such as tumor development, tumor progression, metastasis, and invasion.
While some miRNAs act as tumor suppressors, others may be oncogenic. miRNAs also contribute
to the processes involved in drug resistance. There is increasing evidence demonstrating
the possible effect of miRNAs on the diagnosis and treatment markers of melanoma. The
manuscript focuses on the current challenges in melanoma treatment, highlighting issues such as
the development of resistance and reduced patient responses despite the revolutionary advancements
in targeted therapy and immunotherapy. It underscores the need for small molecule inhibitors
and the creation of biomarkers for predicting patient responses to current treatments. The role
of miRNAs in processes such as tumor development, metastasis, and invasion has been highlighted.
While certain miRNAs function as tumor suppressors, others may exhibit oncogenic properties.
Furthermore, increasing evidence is presented demonstrating the potential significance of
miRNAs as markers for the symptom and identification of melanoma. These findings indicate a
promising avenue for future research and clinical applications. In summary, the article effectively
communicates key insights, making it a valuable resource for those interested in melanoma research
and treatment.